eClinical Tech News

Rhythm Pharmaceuticals reported topline results from EMANATE, a global, randomized, double-blind, placebo-controlled Phase 3 trial of setmelanotide in rare,...

CytomX Therapeutics reported a positive Phase 1 dose-expansion update for varsetatug masetecan, an EpCAM-targeted Probody ADC, in advanced colorectal...

Zenas Biopharma will file a U.S. BLA for obexelimab in IgG4-related disease in Q2 2026, with an EMA submission...

Akari Therapeutics has marked its first year under new leadership with a reset around antibody-drug conjugates, unveiling concrete steps...

Barinthus Biotherapeutics plans to merge with Clywedog Therapeutics in an all-stock deal expected to close in the second quarter...

Tonix Pharmaceuticals has turned the corner from development to commercialization with the U.S. launch of Tonmya, a sublingual cyclobenzaprine...

Korro Bio has nominated KRRO-121 as its next clinical candidate for the treatment of hyperammonemia in urea cycle disorders...

Lyell Immunopharma has begun dosing in a first-of-its-kind phase 3 head-to-head randomized trial in second-line large B-cell lymphoma, testing...

Bolt Biotherapeutics reported 2025 results and advanced its first-in-class immune-stimulating antibody conjugate, BDC-4182, into a Phase 1 dose-escalation study...

Vaxart reported a pivotal business update: enrollment is complete in its approximately 5,400-participant phase 2b COVID-19 trial comparing an...